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Background: Adenosine A2b receptor (ADORA2B) encodes an adenosine receptor that is a member of the G
protein-coupled receptor superfamily. This integral membrane protein stimulates adenylate cyclase activity
in the presence of adenosine. Little is known about the relevance of ADORA2B to human malignancy
including oral squamous cell carcinoma (OSCC). We aimed to characterize the expression state and function
of ADORA2B in OSCC.
Methods: The ADORA2B expression levels in nine OSCC-derived cells were analyzed by quantitative reverse
transcriptase-polymerase chain reaction and immunoblotting analyses. Using an ADORA2B knockdown model,
we assessed cellular proliferation and expression of hypoxia-inducible factor1α (HIF-1α). We examined the
adenosine receptor expression profile under both normoxic and hypoxic conditions in the OSCC-derived cells.
In addition to in vitro data, the clinical correlation between the ADORA2B expression levels in primary OSCCs
(n = 100 patients) and the clinicopathological status by immunohistochemistry (IHC) also was evaluated.
Results: ADORA2B mRNA and protein were up-regulated significantly (p < 0.05) in seven OSCC-derived cells
compared with human normal oral keratinocytes. Suppression of ADORA2B expression with shRNA significantly
(p < 0.05) inhibited cellular proliferation compared with the control cells. HIF-1α also was down-regulated in
ADORA2B knockdown OSCC cells. During hypoxia, ADORA2B expression was induced significantly (p < 0.05)
in the mRNA and protein after 24 hours of incubation in OSCC-derived cells. IHC showed that ADORA2B
expression in primary OSCCs was significantly (p < 0.05) greater than in the normal oral counterparts and that
ADORA2B-positive OSCCs were correlated closely (p < 0.05) with tumoral size.
Conclusion: Our results suggested that ADORA2B controls cellular proliferation via HIF-1α activation,
indicating that ADORA2B may be a key regulator of tumoral progression in OSCCs.Background
The adenosine receptors consists of four members that
belong to the G protein-coupled receptor superfamily,
including A1, A2A, A2B and A3 [1]. Activation of
ADORA2A and ADORA2B causes activation of adenyl-
ate cyclase and phospholipase C [2]. ADORA2B is found
in many different cellular types and requires higher
concentrations of adenosine for activation than the* Correspondence: uzawak@faculty.chiba-u.jp
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creativecommons.org/publicdomain/zero/1.0/ADORA1, 2A, and 3 subtypes [2]. ADORA2B mainly is
located peripherally and is involved in inflammation and
immune response [3]. ADORA2B is not stimulated by
physiologic levels of adenosine and therefore may play
an important role in pathophysiologic conditions associ-
ated with massive adenosine release. Such conditions
occur in tumors when hypoxia is commonly observed
[4, 5]. Moreover, ADORA2B was overexpressed in colo-
rectal carcinomas grown under hypoxic conditions [6].
Adenosine was reported to modulate proliferation of
cancer cells by a hypoxia-inducible factor1α (HIF-1α)-
dependent mechanism [7]. HIF-1 expression and activity
also are regulated by important signal transduction path-
ways including those involving extracellular regulatedrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ADORA2B may be associated with cancer progression.
Growing evidence indicates that the adenosine-receptor
pathway also may be a promising therapeutic target in a
wide range of conditions, including cerebral and cardiac
ischemic diseases, sleep disorders, immune and inflamma-
tory disorders, and cancer [9]. However, the expression
status and function of ADORA2B in oral squamous car-
cinoma (OSCC) have not been characterized fully.
Because the relationship between HIF-1α and ADORA2B
is just beginning to be understood, we assumed that
dysregulation of ADORA2B is involved in progression of
OSCCs via activation of HIF-1α. We also performed func-




The Ethics Committee of the Graduate School of Medi-
cine, Chiba University (approval number, 236) approved
the study protocol, which was performed according to
the tenets of the Declaration of Helsinki. All patients
provided written informed consent.
OSCC-derived cellular lines and tissue specimens
Immortalized human OSCC-derived cell lines (HSC-2,
HSC-3, HSC-4, Ca9-22, Sa3, HO-1-u-1, HO-1-N-1,
KOSC2, and SAS) were obtained from the Human Sci-
ence Research Resources Bank (Osaka, Japan) or the
RIKEN BioResource Center (Ibaraki, Japan) through the
National BioResource Project of the Ministry of Educa-
tion, Culture, Sports, Science and Technology (Tokyo,
Japan). Short tandem repeat profiles confirmed cellular
identity. All OSCC-derived cells were grown in Dulbec-
co’s modified Eagle medium/F-12 HAM (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10 % fetal bo-
vine serum (Sigma-Aldrich) and 50 units/ml penicillin
and streptomycin (Sigma-Aldrich). Isolated and primary-
cultured human normal oral keratinocytes (HNOKs)
were used as a normal tissue control [10-15]. They were
isolated from healthy oral mucosal epithelial specimens
from three young patients at Chiba University Hospital.
The HNOKs were primary cultured and maintained in
Keratinocyte-SFM (Invitrogen, Carlsbad, CA, USA) com-
prised of growth supplement (Invitrogen) and 50 units/
ml penicillin and streptomycin (Sigma).
One hundred pairs of primary OSCC samples and cor-
responding normal oral epithelial tissues were obtained
during surgeries at Chiba University Hospital. The
resected tissues were fixed in 20 % buffered formalde-
hyde solution for pathologic diagnosis and immunohis-
tochemistry (IHC). The Department of Pathology of
Chiba University Hospital histopathologically diagnosed
each OSCC sample according to the World HealthOrganization criteria [16]. Clinicopathologic staging was
determined by the TNM (tumor-node-metastasis) classi-
fication of the International Union against Cancer [17].
All patients had OSCC that was confirmed histologically;
the samples were checked to ensure that tumoral tissue
was present in more than 80 % of the specimens.
Preparation of cDNA and protein
Total RNA was isolated using Trizol Reagent (Invitro-
gen) according to the manufacturer’s instructions. cDNA
was generated using 5 μg total RNA from OSCC-derived
cell lines using Ready-To-Go You-Prime First-Strand
Beads (GE Healthcare, Buckinghamshire, UK) and oligo
(dT) primer (Hokkaido System Science, Sapporo, Japan)
according to the manufacturer’s instructions. The cells
were washed twice with cold phosphate-buffered saline
(PBS) and centrifuged briefly. The cell pellets were incu-
bated at 4 °C for 30 minutes in a lysis buffer (7 M urea,
2 M thiourea, 4 % w/v CHAPS, and 10 mM Tris pH 7.4)
with a proteinase inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). HNOKs proteins were extracted
from the same samples obtained for RNA. The protein
concentration was measured using the BCA Protein
Assay Kit (Thermo, Rockford, IL, USA).
mRNA expression analysis
Real-time quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) was performed using the Light-
Cycler 480 apparatus (Roche Diagnostics). Primers and
universal probes were designed using the Universal Probe
Library (Roche Diagnostics), which specifies the most suit-
able set. The primer sequences used for qRT-PCR were:
ADORA2B, forward, 5′-GGGCTTCTGCACTGACTTCT
-3′; reverse, 5′-CCGTGACCAAACTTTTATACCTG -3′;
and universal probe #34, and the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) , forward, 5′-AGC
CACATCGCTCAGACAC -3′; reverse, 5′-GCCCAATAC
GACCAAATCC -3′; and universal probe #60. The tran-
script amount for ADORA2B was estimated from the
respective standard curves and normalized to the
GAPDH transcript amount determined in correspond-
ing samples. All samples were analyzed in triplicate,
and three independent RNA preparations were ana-
lyzed from each cell line.
Immunoblotting analysis
Protein extracts (20 μg) were separated by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis in 4-12 %
gel, transferred to nitrocellulose membranes, and
blocked for 1 hour at room temperature in Blocking
One (Nacalai Tesque, Tokyo, Japan). The membranes
were incubated with rabbit anti-ADORA2B polyclonal
antibody (Chemicon International, Temecula, CA, USA),
mouse anti-α tubulin monoclonal antibody (Santa Cruz
Fig. 1 Evaluation of ADORA2B expression in OSCC-derived cell lines.
a Quantification of ADORA2B mRNA expression in OSCC-derived cell
lines by qRT-PCR analysis. Significant (p < 0.05, Mann–Whitney U test)
up-regulation of ADORA2B mRNA is seen in seven OSCC-derived
cell lines compared with the HNOKs. Data are expressed as the
means ± SEM of triplicate results. b Representative immunoblotting
analysis of ADORA2B protein in OSCC-derived cell lines and HNOKs.
ADORA2B protein expression is up-regulated in OSCC-derived cell
lines compared with the HNOKs. Densitometric ADORA2B protein
data are normalized to α-tubulin protein levels. The values are
expressed as a percentage of the HNOKs
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1α monoclonal antibody (Santa Cruz Biotechnology),
rabbit anti-Akt monoclonal antibody (Santa Cruz Bio-
technology), rabbit anti-pAkt monoclonal antibody
(Santa Cruz Biotechnology) , rabbit anti-ERK1/2 mono-
clonal antibody (Santa Cruz Biotechnology), and rabbit
anti-pERK1/2 monoclonal antibody (Santa Cruz Biotech-
nology) overnight at 4 °C. The membranes were washed
with 0.1 % Tween-20 in Tris-buffered saline, incubated
with secondary antibody and coupled to horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG
(Promega, Madison, WI, USA) for 1 hour at room
temperature. The membranes were detected using
SuperSignal West Pico Chemiluminescent substrate
(Thermo), and immunoblotting was visualized by expos-
ing the membranes to ATTO Light-Capture II (ATTO,
Tokyo, Japan). Signal intensities were quantitated using
the CS Analyzer version 3.0 software (ATTO).
Transfection with shRNA plasmid
OSCC cellular lines (HSC-3 and -4) were transfected with
ADORA2B shRNA (shADORA2B) or control shRNA
(shMock) vectors (Santa Cruz Biotechnology) using Lipo-
fectamine LTX and Plus Reagents (Invitrogen). After
transfection, the stable transfectants were isolated by a
culture medium containing 2 ng/mL Puromycin (Invitro-
gen). Two to three weeks after transfection, viable colonies
were transferred to new dishes. shADORA2B and shMock
cells were used for further experiments.
Cellular growth
The transfectants were seeded in six-well plates at a dens-
ity of 1 × 104 viable cells/well. Cells were harvested for
168 hours and counted every 24 hours. We determined
proliferation rates using the 3-(4, 5-dimethylthiazol-2-yl)-
5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium (MTS) assay (Promega).
Apoptosis assay
Apoptosis detection was performed in transfected and
control cells by staining with the Annexin V-FITC
Apoptosis Detection kit (Abcam, Cambridge, MA, USA).
Cells were harvested at a density of 2×105 cells/ml in
1 × binding buffer and stained with FITC-labeled
Annexin V and propidium iodide (PI) for 5 min at room
temperature. Samples were immediately analyzed using
the FACScaliber flow cytometer (Becton-Dickinson, San
Jose, CA, USA).
Hypoxic treatment
To create hypoxia, cells were placed for 12 to 48 hours
in a modular incubator chamber (Astec, Fukuoka, Japan)
and flushed with a gas mixture containing 1 % oxygen,
5 % carbon dioxide, and balance N2.IHC
IHC was performed on 4-μm sections of paraffin-
embedded specimens using rabbit anti-ADORA2B poly-
clonal antibody (Chemicon International) and mouse
anti- HIF-1α monoclonal antibody (Santa Cruz Biotech-
nology). Briefly, after deparaffinization and hydration,
the endogenous peroxidase activity was quenched by a
30-minute incubation in a mixture of 0.3 % hydrogen
peroxide solution in 100 % methanol; the sections were
blocked for 2 hours at room temperature with 1.5 %
blocking serum (Santa Cruz Biotechnology) in PBS
before reacting with anti-ADORA2B antibody overnight
at 4 °C in a moist chamber. Upon incubation with the
Kasama et al. BMC Cancer  (2015) 15:563 Page 4 of 12primary antibody, the specimens were washed three
times in PBS and treated with Envision reagent (DAKO,
Carpinteria, CA, USA) followed by color development in
3,3′-diaminobenzidine tetrahydrochloride (DAKO). The
slides then were counterstained slightly with hematoxylin,
dehydrated with ethanol, cleaned with xylene, and
mounted. Nonspecific binding of an antibody to proteins
other than the antigen sometimes occurred. As a negative
control, triplicate sections were immunostained withoutFig. 2 Evaluation of ADORA2B protein expression in primary OSCCs. a, b R
primary OSCC. a Normal oral tissues show almost negative immunostaining
cases of OSCC. Positive immunoreaction for ADORA2B is detected in th
c The status of ADORA2B protein expression in primary OSCCs (n = 100
IHC scores are calculated as follows: IHC score = 1 × (number of weakly
in the field) + 3 × (number of intensely stained cells in the field). The A
20 to 110 (median, 51) and 99 to 245 (median, 139.5), respectively. AD
(p < 0.05, Mann–Whitney U test) higher than in normal oral tissues. d K
OSCCs based on the levels of ADORA2B expression. Up-regulated ADO
rates (N.S. = p = 0.8037). The log-rank statistic was used to test the diff
up-regulated ADORA2B; ADORA2B (−), down-regulated ADORA2Bexposure to primary antibodies, which confirmed the
staining specificity. To quantify the status of ADORA2B
protein expression in those components, we used the IHC
scoring systems described previously [13, 15, 18-20]. The
mean percentages of positive tumoral cells were deter-
mined in at least three random fields at 400× magnifica-
tion in each section. The intensities of the ADORA2B
immunoreactions were scored as follows: 0+, none; 1+,
weak; 2+, moderate; and 3+, intense. The cellular numberepresentative IHC results of ADORA2B in normal oral tissue and
. Original magnification, ×100. Scale bars, 50 mm. b ADORA2B-positive
e cytoplasm. Original magnification, ×400. Scale bars, 10 mm.
) and the normal counterparts based on an IHC scoring system.
stained cells in the field) + 2 × (number of moderately stained cells
DORA2B IHC scores for normal oral tissues and OSCCs range from
ORA2B protein expression levels in OSCCs are significantly
aplan–Meier survival curve for overall survival rates of patients with
RA2B expression was not significantly related to overall survival
erence in survival times between the groups. ADORA2B (+),










Age at surgery (years)
<60 27 7 (26) 20 (74) 0.95
≧60, <70 26 8 (31) 18 (69)
≧70 47 13 (28) 34 (72)
Gender
Male 64 21 (33) 43 (67) 0.24
Female 36 7 (19) 29 (81)
T-primary tumor
T1 8 3 (38) 5 (62) 0.02*
T2 60 22 (37) 38 (63)
T3 15 2 (13) 13 (87)
T4 17 1 (6) 16 (94)
T1 + T2 58 25 (43) 33 (57) 0.01*
T3 + T4 32 3 (10) 29 (90)
N-regional lymph node
N (negative) 58 14 (24) 44 (76) 0.39
N (positive) 42 14 (33) 28 (67)
Stage
I 7 3 (43) 4 (57) 0.54
II 38 11 (29) 27 (71)
III 17 4 (24) 13 (76)
IV 38 10 (26) 28 (74)
Histopathologic type
Well 64 15 (23) 49 (77) 0.25
Moderately 31 11 (35) 20 (65)
Poorly 5 2 (40) 3 (60)
Tumor site
Gingiva 35 11 (31) 24 (69) 0.84
Tongue 50 12 (24) 38 (76)
Buccal mucosa 9 2 (22) 7 (78)
Oral floor 6 3 (50) 3 (50)
p < 0.05
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ADORA2B IHC score. Cases with an ADORA2B IHC
score exceeding 120.0 (+3 standard deviation [SD] score
for normal tissue) were defined as ADORA2B-positive.
The ±3-SD cutoff, which statistically is just 0.2 % of the
measurement and would be expected to fall outside this
range, was used because it was unlikely to be affected by
random experimental error produced by sample manipu-
lation [21]. Two independent pathologists from Chiba
University Hospital, neither of whom had knowledge of
the patients’ clinical status, made these judgments.
Statistical analysis
In comparisons of ADORA2B expression levels, statistical
significance was evaluated using the Mann–Whitney U test.
Relationships between ADORA2B-immunohistochemical
staining scores and clinicopathological profiles were
evaluated using the χ2 test, Fisher’s exact test, and
Mann–Whitney U test. p < 0.05 was considered sig-
nificant. The data are expressed as the mean ± stand-
ard error of the mean (SEM). Survival curves were
obtained by the Kaplan–Meier method, and differ-
ences in survival rates between ADORA2B-positive
and ADORA2B negative cases were compared by log-
rank test with 95 % significance.
Results
Evaluation of ADORA2B expression in OSCC-derived cell
lines
To analyze the expression status of ADORA2B, we per-
formed qRT-PCR and immunoblotting analysis using
nine OSCC-derived cell lines (HSC-2, HSC-3, HSC-4,
Cap-22, Sa3, Ho-1-u-1, Ho-1-N-1, KOSC2, and SAS)
and HNOKs. ADORA2B mRNA was up-regulated sig-
nificantly (p < 0.05) in seven OSCC-derived cell lines
compared with the HNOKs (Fig. 1a). Figure 1b shows rep-
resentative results of immunoblotting analysis. ADORA2B
protein expression increased significantly in all OSCC-
derived cell lines compared with the HNOKs. Expression
analysis indicated that both transcription and translation
products of this molecule were highly expressed in the
OSCC-derived cell lines.
Evaluation of ADORA2B expression in primary OSCCs
To determine the expression status of ADORA2B in pri-
mary OSCCs and the relation to the clinicopathological
characteristics, we investigated ADORA2B protein
expression in primary OSCCs and paired normal oral
tissues from 100 patients using the IHC scoring system.
Representative IHC results for ADORA2B protein in the
normal oral tissue and primary OSCC are shown in
Fig. 2a-c. Positive staining was seen predominantly in
the cytoplasm of primary OSCC samples (Fig. 2b). The
ADORA2B IHC scores in primary OSCCs (range, 99-245; median, 139.5) were significantly higher than in
normal tissues (20-110; median, 51) (Fig. 2c) (p < 0.05).
Table 1 shows the correlations between the clinicopatho-
logical characteristics of the patients with OSCC and the
status of ADORA2B protein expression using the IHC
scoring system. We defined cases with an IHC score
exceeding 120 (+3-SD score for normal tissue) as
ADORA2B-positive. Among the clinical parameters,
ADORA2B expression was related significantly (p = 0.02)
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nificant (p = 0.01) difference was found in the ADORA2B
expression levels between the T1/T2 group and the T3/T4
group. Survival analysis using the Kaplan–Meier method
showed that ADORA2B expression was not significantly
related to overall survival (P = 0.8037; Fig. 2d).Fig. 3 Expression of ADORA2B in shADORA2B-transfected cells. a Expressio
(HSC-3- and -4-derived transfectants). The ADORA2B mRNA expression in th
than that in the shMock-transfected cells. b Immunoblotting analysis of AD
(HSC-3- and -4-derived transfectants). The ADORA2B protein in the shADOR
shMock-transfected cellsEstablishment of ADORA2B knockdown cells
The OSCC-derived cell lines (HSC-3 and -4) were trans-
fected with ADORA2B shRNA (shADORA2B) and the
control shRNA (shMock). qRT-PCR and immunoblotting
analyses were performed to assess the efficiency of
ADORA2B knockdown. ADORA2B mRNA expression inn of ADORA2B mRNA in shMock- and shADORA2B-transfected cells
e shADORA2B is significantly (p < 0.05, Mann–Whitney U test) lower
ORA2B protein in the shMock- and shADORA2B-transfected cells
A2B transfected cells is decreased markedly compared with the
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lower than in shMock-transfected cells (Fig. 3).
Reduced cellular growth in ADORA2B knockdown cells
To study the effect of ADORA2B knockdown on cellular
growth, we performed a cellular proliferation assay.
shADORA2B and shMock cells were seeded in six-well
plates at a density of 1 × 104 viable cells/well that were
counted for 168 hours. Both HSC-3 and -4 shADORA2B
cells had a significant (p < 0.05) decrease in cellular growth
compared with the shMock cells (Fig. 4a). To confirm
apoptotic activity, shADORA2B and shMock cells were an-
alyzed for Annexin V expression by flow cytometry. There
was no significant difference in the percentage of annexin-Fig. 4 Proliferation and apoptosis assay of shADORA2B-transfected cells
shADORA2B- and shMock-transfected cells were seeded in six-well plates at a
and -4 cells have significantly (p < 0.05, Mann–Whitney U test) decreased cellu
rate was assayed using flow cytometry after staining with Annexin V-FITC andV and PI positive cells in the shADORA2B and shMock
cells (Fig. 4b).Hypoxic induction of ADORA2B
To investigate the relationship between ADORA2B ex-
pression and oxygen supply, we examined ADORA2B
expression under both normoxic and hypoxic conditions
in the OSCC-derived cell lines (HSC-3 and -4, with
higher ADORA2B protein expression). The expression
of ADORA2B mRNA and protein were up-regulated
significantly (p < 0.05) in these cell lines after 24 hours
of hypoxia compared with a normoxia (Fig. 5a, b).
Immunocytofluorescence showed that the ADORA2B. a To determine the effect of shADORA2B on cellular proliferation,
density of 1 × 104 viable cells/well. The shADORA2B transfected HSC-3
lar growth compared with the shMock-transfected cells. b The apoptosis
propidium iodide
Fig. 5 (See legend on next page.)
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Fig. 5 Hypoxic induction of ADORA2B. a OSCC-derived cell lines are exposed to hypoxia (1 % oxygen ) and probed for ADORA2B expression by
qRT-PCR. Expression of ADORA2B mRNA is induced significantly (p < 0.05, Mann–Whitney U test) by hypoxia in OSCC-derived cell lines (HSC-3
and -4). b Immunoblotting analysis shows that the ADORA2B protein levels in hypoxia also have increased markedly compared with that in
normoxia. c Immunocytofluorescence labeling of ADORA2B (red). Cellular nuclei are labeled with DAPI (blue). Immunocytofluorescence shows that
the ADORA2B expression levels are higher in hypoxia than in normoxia in OSCC-derived cell lines (HSC-3 and -4)
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moxia in these cell lines (Fig. 5c).
Activation of HIF-1α
To investigate a potential underlying mechanism of re-
duced cellular proliferation in the shADORA2B-
transfected cells, we assessed the HIF-1α pathways.
ADORA2B knockdown causes markedly decreased pro-
tein expression levels of HIF-1α compared with
shMock-transfected cells (Fig. 6). To evaluate the status
of the protein expressions of ERK1/2 phosphorylation
(pERK1/2) and Akt phosphorylation (pAkt), we per-
formed immunoblotting analyses in the shADORA2B
transfected cells. ADORA2B knockdown caused mark-
edly decreased levels of pERK1/2 and pAkt compared
with shMock-transfected cells. Results from immuno-
blotting analyses indicated that the phosphorylation
levels of ERK1/2 and Akt decreased, whereas ERK1/2
and Akt proteins were unchanged (Fig. 6). Moreover, to
evaluate the status of the protein expressions of HIF-1α,
pERK1/2, and pAkt under hypoxic conditions, we per-
formed immunoblotting analyses in the shMock cells
and shADORA2B-transfected cells. HIF-1α, pERK1/2,
and pAkt expression levels were higher in hypoxia than
in normoxia. During a hypoxic conditions, the levels of
HIF-1α, pERK1/2, and pAkt protein were not increased
significantly in the shADORA2B-transfected cells (Fig. 6).
In addition to the in vitro data, we also investigated the
correlation of ADORA2B and HIF-1α in ADORA2B-
positive clinical samples by IHC staining. The high
expression of HIF-1α protein was detected in 19 out of
20 these samples (Additional file 1).
Discussion
There is growing evidence that adenosine receptor ago-
nists are attractive therapeutic targets for a number of
conditions, including inflammation and certain cancer
types [1, 22-27]. Adenosine receptors are found to be
up-regulated in various tumoral cells [28]. ADORA2B
has important roles in cellular proliferation and differen-
tiation and apoptosis of tumoral cells [29-31]. Our previ-
ous microarray data showed significant up-regulation of
ADORA2B in OSCC-derived cell lines [32]. The current
study found a high prevalence of increased ADORA2B
expression in patients with OSCC and a significant cor-
relation with the primary tumoral size (Table 1). These
findings indicated that ADORA2B overexpression maybe linked to human oral carcinogenesis, has an import-
ant role in OSCC development, and is related closely to
tumoral progression. However, the detailed function of
ADORA2B in OSCC remains unclear. To determine
whether ADORA2B function is relevant to OSCC pro-
gression, we performed functional analysis to define the
biologic effect of ADORA2B.
A significant up-regulation of ADORA2B was detected
in all OSCC-derived cells examined at protein levels
(Fig. 1b), indicating that ADORA2B expression is neces-
sary for oral carcinogenesis. On the other hand, the
mRNA expression states depended on the cells (Fig. 1a).
A possible explanation for this discrepancy is that
ADORA2B proteins are differently affected by the post-
translational ubiquitination and proteolysis in each tumor
cell lines. In this context, discrepancies between mRNA
expression levels and protein levels has been reported in
OSCC cellular lines [33]. Many studies have indicated that
ADORA2B plays critical roles, including tumoral develop-
ment and progression, in cancers [3, 5-7, 31, 32]. In con-
trast, some studies have reported that ADORA2B has no
role in adenosine-induced proliferation of human melan-
oma cells [34]. ADORA2B was up-regulated consistently
in colorectal carcinoma tissues and colon cancer cell lines
compared with normal colorectal mucosa [6].
The current study showed that hypoxia was involved
with ADORA2B up-regulation in OSCC cells (Fig. 5a, b).
Most solid tumors do not receive sufficient oxygen and
tumoral cells grow in hypoxia [6]. Hypoxia promotes re-
lease of vascular endothelial growth factor by increasing
ADORA2B expression and decreasing ADORA2A expres-
sion in human endothelial and smooth muscle cells [35].
Intratumoral hypoxia and genetic alterations lead to
HIF-1α overexpression, which has been associated with
increased patient mortality in several cancer types [36].
To date, expression of ADORA2B correlation with HIF-1α
expression have not been elucidated in OSCC tissues. Our
data showed that the immunoexpression of ADORA2B
was correlated with HIF-1α expression in primary OSCCs
(Additional file 1). HIF-1α is a common transcription fac-
tor induced by ADORA2B activation in inflammatory
bowel disease and urologic diseases [37, 38]. Based on
these findings, we observed the expression status of HIF-
1α in the ADORA2B knockdown cells. As expected, HIF-
1α was down-regulated significantly in the ADORA2B
knockdown cells. We assessed the ERK1/2 and Akt path-
ways, which are up-regulated frequently in other cancers
Fig. 6 ADORA2B knockdown inhibits HIF-1α, Akt, and ERK1/2 activation. Immunoblotting analysis of ADORA2B, HIF-1α, pERK1/2, and pAkt proteins in
the Mock and shADORA2B cells under both normoxic and hypoxic conditions. The expression of ADORA2B, HIF-1α, pERK1/2, and pAkt protein were
up-regulate in the shMock cells of hypoxia compared with a normoxia. The HIF-1α protein levels in the shADORA2B-transfected cells (HSC-3- and -4-
derived transfectants) also have decreased markedly compared with that in the shMock-transfected cells under both normoxic and hypoxic conditions.
ADORA2B knockdown causes decreased levels of pAkt and pERK1/2 compared with the shMock-transfected cells (HSC-3- and -4-derived transfectants);
the AKT and ERK1/2 protein levels are unchanged under both normoxic and hypoxic conditions. Densitometric ADORA2B, HIF-1α, pAkt/Akt and pERK/
ERK protein data were normalized to the α-tubulin protein levels
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phorylation levels of ERK1/2 and Akt decreased, whereas
ERK1/2 and Akt proteins were unchanged. Moreover,results from immunoblotting analyses indicated that hyp-
oxia promotes the up-regulation of HIF-1α, pERK1/2, and
pAkt by increasing ADORA2B expression (Fig. 6). ERK1/2
Kasama et al. BMC Cancer  (2015) 15:563 Page 11 of 12and Akt activities are required by ADORA2B receptor acti-
vation [7]. The ADORA2B antagonist MRE 2029 F20 re-
duced ERK1/2 and Akt phosphorylation levels in
melanoma cells in hypoxia [39].
Conclusion
The current results indicated that ADORA2B is overex-
pressed frequently in OSCCs and may be associated
strongly with tumoral progression. During hypoxia, there
was significant up-regulation of ADORA2B expression
in OSCC-derived cell lines. While further studies are
needed to determine the interaction between ADORA2B
and HIF-1α, the current data indicated that ADORA2B
may be an efficacious treatment target in progression of
primary OSCCs.
Additional file
Additional file 1: Evaluation of ADORA2B and HIF-1α expression in
primary OSCCs. (A-D) Representative IHC results of ADORA2B and
HIF-1α in the same OSCC samples. (A, B) ADORA2B-positive cases of
OSCC. Positive immunoreaction for ADORA2B is detected in the cytoplasm.
Original magnification, ×100 (A) and × 400 (C). (C, D) HIF-1α-positive cases
of OSCC. Positive immunoreaction for HIF-1α is detected in the nuclear and
cytoplasm. Original magnification, ×100 (C) and × 400 (D). (TIFF 4229 kb)
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